Jamshedpur Reporter

DelveInsight’s “Gastroparesis Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Gastroparesis, historical and forecasted epidemiology as well as the Gastroparesis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Gastroparesis Market Report:

https://www.delveinsight.com/report-store/gastroparesis-market

Some of the key facts of the Gastroparesis Market Report:

• The Gastroparesis market size was valued at approximately USD 150 million in 2025 and is expected to reach nearly USD 970 million by 2036, expanding at a CAGR of 18% during the forecast period from 2026 to 2036.

• In April 2026, Dr. Falk Pharma GmbH and Renexxion Ireland announced that data from the Global Phase IIb (MOVE-IT) study of naronapride in 328 adults with moderate-to-severe idiopathic or diabetic gastroparesis had been selected for a late-breaking oral presentation at DDW 2026 in the US.

• In March 2026, CinDome Pharma announced the completion of patient enrollment in its Phase 2 envisionGI trial evaluating deudomperidone (CIN-102) for adults with idiopathic gastroparesis. Deudomperidone, a novel chemical entity, is being developed to alleviate symptoms of gastroparesis, a condition affecting an estimated 16 million people in the United States and currently lacking FDA-approved long-term treatment options. Topline safety and efficacy results from the envisionGI study are anticipated in the second half of 2026.

• In September 2025, CinDome Pharma, a CinRx portfolio company focused on developing safe, long-term treatments for gastroparesis, announced the completion of enrollment in the envision3D Phase 2 trial of deudomperidone for adults with diabetic gastroparesis. Topline safety and efficacy data are expected in Q1 2026.

• In June 2025, CinDome Pharma announced that the first participant had been dosed in the ENVISION GI Phase II clinical trial of CIN-102 in adults with idiopathic gastroparesis. Based on a strong safety signal and notable reductions in nausea and vomiting symptoms observed in a blinded interim analysis of the ongoing Phase II Envision3D study in patients with diabetic gastroparesis, CinDome has raised an additional USD 40 million of new capital to initiate this Phase II trial to investigate deudomperidone as a treatment for a broader population of patients with this chronic disease.

• In May 2025, Renexxion Ireland, in collaboration with its partner Dr. Falk Pharma GmbH, announced the successful completion of patient enrollment for the global Phase IIb MOVE-IT study evaluating the safety and efficacy of naronapride for the treatment of gastroparesis. The MOVE-IT study achieved its target enrolment of 320 patients.

• In January 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) provided an update on tradipitant’s development, confirming that it has accepted the FDA’s offer for a hearing on the New Drug Application for the treatment of gastroparesis.

• Among the 7MM, the US represented the largest gastroparesis market, valued at approximately USD ~150 million in 2025, and is projected to grow at a significant CAGR through 2036.

• Currently, the majorly prescribed class of therapies is prokinetics, such as oral or IV metoclopramide antiemetics and neuromodulators to manage symptoms.

• Among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of gastroparesis with ~724,000 cases in 2025.

• In the US in 2025, the highest age-specific cases were seen in the 65+ age group, followed by those aged 48–57, while the lowest were in the 18–27 age group.

• Gastroparesis as a disease predominantly affects women, with ~70% of the diagnosed patients being females, while only ~30% of the diagnosed patients are males.

• Among etiology-specific cases across the 7MM, diabetes has the highest prevalence, followed by postsurgical causes, drug-induced cases, and then idiopathic cases.

• Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others

• Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others

• The Gastroparesis epidemiology based on gender analyzed that Gastroparesis cases were higher in females in comparison to males, in all the 7MM countries

• The Gastroparesis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Gastroparesis pipeline products will significantly revolutionize the Gastroparesis market dynamics.

Gastroparesis Overview

Gastroparesis is a medical condition characterized by delayed emptying of the stomach contents into the small intestine, without the presence of any mechanical obstruction. This delay in gastric emptying can lead to symptoms such as nausea, vomiting, bloating, early satiety (feeling full quickly after eating), abdominal pain, and a lack of appetite.

To Know in detail about the Gastroparesis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Gastroparesis Market Forecast

Gastroparesis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Gastroparesis Epidemiology Segmentation:

The Gastroparesis market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Diagnosed Prevalent Cases of Gastroparesis

• Etiology-specific Cases of Gastroparesis

• Gender-specific Diagnosed Prevalent Cases of Gastroparesis

• Age-specific Diagnosed Prevalent Cases of Gastroparesis

• Total Cases of Gastroparesis by the Severity of Delayed Gastric Emptying

• Treated cases of Gastroparesis

Download the report to understand which factors are driving Gastroparesis epidemiology trends @ Gastroparesis Epidemiology Forecast

Gastroparesis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastroparesis market or expected to get launched during the study period. The analysis covers Gastroparesis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Gastroparesis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Gastroparesis Therapies and Key Companies

• Naronapride (ATI-7505): Renexxion

• CIN-102 (deudomperidone): CinDome Pharma

• NG101 (metopimazine): Neurogastrx

• PCS12852: Processa Pharma/Intact Therapeutics

• Metoclopramide Nasal Spray: Evoke Pharma

• Tradipitant: Vanda Pharmaceuticals

• IW-9179: Ironwood Pharmaceuticals

• TAK-954: Takeda

• NG101: Neurogastrx, Inc

• CNSA-001: PTC Therapeutics

• velusetrag: Theravance Biopharma

• GM-611: Chugai Pharma

• Camicinal: GlaxoSmithKline

• PCS12852: Processa Pharmaceuticals

Discover more about therapies set to grab major Gastroparesis market share @ Gastroparesis Treatment Market

Gastroparesis Market Drivers

• Rising prevalence of diabetes mellitus, a major risk factor for gastroparesis, is increasing the patient population requiring treatment.

• Growing awareness and improved diagnostic techniques, including gastric emptying studies and advanced imaging methods, are supporting earlier diagnosis.

• Significant unmet medical need and limited effective treatment options are driving demand for novel therapeutics.

• A strong pipeline of emerging prokinetic agents and innovative therapies is expected to expand the treatment landscape and fuel market growth.

Gastroparesis Market Barriers

• Limited availability of approved therapies with long-term efficacy and safety data remains a major challenge in disease management.

• Complex and heterogeneous disease presentation can complicate diagnosis, treatment selection, and clinical trial design.

• Potential side effects associated with existing prokinetic medications may limit their long-term use and patient adherence.

• Lack of standardized treatment guidelines and variability in clinical practice can affect treatment outcomes.

Scope of the Gastroparesis Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Gastroparesis Companies: CinDome Pharma, Inc., Evoke Pharma, Vanda Pharmaceuticals, Ironwood Pharmaceuticals, Takeda, Neurogastrx, Inc, PTC Therapeutics, Theravance Biopharma, Chugai Pharma, GlaxoSmithKline, Processa Pharmaceuticals, and others

• Key Gastroparesis Therapies: CIN-102, Metoclopramide Nasal Spray, Tradipitant, IW-9179, TAK-954, NG101, CNSA-001, velusetrag, GM-611, Camicinal, PCS12852, and others

• Gastroparesis Therapeutic Assessment: Gastroparesis current marketed and Gastroparesis emerging therapies

• Gastroparesis Market Dynamics: Gastroparesis market drivers and Gastroparesis market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Gastroparesis Unmet Needs, KOL’s views, Analyst’s views, Gastroparesis Market Access and Reimbursement

To know more about Gastroparesis companies working in the treatment market, visit @ Gastroparesis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Gastroparesis Market Report Introduction

2. Executive Summary for Gastroparesis

3. SWOT analysis of Gastroparesis

4. Gastroparesis Patient Share (%) Overview at a Glance

5. Gastroparesis Market Overview at a Glance

6. Gastroparesis Disease Background and Overview

7. Gastroparesis Epidemiology and Patient Population

8. Country-Specific Patient Population of Gastroparesis

9. Gastroparesis Current Treatment and Medical Practices

10. Gastroparesis Unmet Needs

11. Gastroparesis Emerging Therapies

12. Gastroparesis Market Outlook

13. Country-Wise Gastroparesis Market Analysis (2022–2036)

14. Gastroparesis Market Access and Reimbursement of Therapies

15. Gastroparesis Market Drivers

16. Gastroparesis Market Barriers

17. Gastroparesis Appendix

18. Gastroparesis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/